NZ600907A - Progestin/estradiol transdermal gel - Google Patents

Progestin/estradiol transdermal gel

Info

Publication number
NZ600907A
NZ600907A NZ600907A NZ60090710A NZ600907A NZ 600907 A NZ600907 A NZ 600907A NZ 600907 A NZ600907 A NZ 600907A NZ 60090710 A NZ60090710 A NZ 60090710A NZ 600907 A NZ600907 A NZ 600907A
Authority
NZ
New Zealand
Prior art keywords
progestin
female
estradiol
sufficient
daily dose
Prior art date
Application number
NZ600907A
Other languages
English (en)
Inventor
Dario Norberto Ramon Carrara
Regine Sitruk-Ware
Arnaud Grenier
Original Assignee
Population Council Inc
Antares Pharma Ipl Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc, Antares Pharma Ipl Ag filed Critical Population Council Inc
Publication of NZ600907A publication Critical patent/NZ600907A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ600907A 2009-12-17 2010-12-17 Progestin/estradiol transdermal gel NZ600907A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751409P 2009-12-17 2009-12-17
PCT/US2010/060941 WO2011084668A1 (en) 2009-12-17 2010-12-17 Nestorone®/estradiol transdermal gel

Publications (1)

Publication Number Publication Date
NZ600907A true NZ600907A (en) 2013-11-29

Family

ID=43640394

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600907A NZ600907A (en) 2009-12-17 2010-12-17 Progestin/estradiol transdermal gel

Country Status (14)

Country Link
US (1) US9682087B2 (enExample)
EP (1) EP2512486B1 (enExample)
JP (1) JP6082249B2 (enExample)
KR (2) KR20120107492A (enExample)
CN (1) CN102753180A (enExample)
AU (1) AU2010339867B2 (enExample)
BR (1) BR112012014059B1 (enExample)
CA (1) CA2782075C (enExample)
ES (1) ES2641613T3 (enExample)
IN (1) IN2012DN04867A (enExample)
MX (1) MX363536B (enExample)
NZ (1) NZ600907A (enExample)
WO (1) WO2011084668A1 (enExample)
ZA (1) ZA201204267B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN117396195A (zh) * 2021-03-30 2024-01-12 晖致公司 具有低剂量雌激素的透皮系统及其制造和使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133077T2 (de) 1990-06-01 2002-11-07 The Population Council, New York Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
JPH04342531A (ja) 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収製剤
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2011049948A2 (en) * 2009-10-19 2011-04-28 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®

Also Published As

Publication number Publication date
CA2782075C (en) 2015-06-30
EP2512486A1 (en) 2012-10-24
KR20180084149A (ko) 2018-07-24
JP2013514984A (ja) 2013-05-02
IN2012DN04867A (enExample) 2015-09-25
BR112012014059A2 (pt) 2016-07-05
KR20120107492A (ko) 2012-10-02
KR101928321B1 (ko) 2018-12-12
ES2641613T3 (es) 2017-11-10
MX2012006755A (es) 2012-11-23
ZA201204267B (en) 2013-01-31
EP2512486B1 (en) 2017-06-28
MX363536B (es) 2019-03-27
WO2011084668A1 (en) 2011-07-14
AU2010339867B2 (en) 2014-07-24
AU2010339867A1 (en) 2012-07-19
JP6082249B2 (ja) 2017-02-15
BR112012014059B1 (pt) 2020-03-10
US9682087B2 (en) 2017-06-20
US20130045953A1 (en) 2013-02-21
CA2782075A1 (en) 2011-07-14
CN102753180A (zh) 2012-10-24
BR112012014059A8 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
NZ600907A (en) Progestin/estradiol transdermal gel
JP2013514984A5 (enExample)
GB2475013A (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
MX2009013427A (es) Uso de estirol en bajas dosis.
PH12014501000A1 (en) Dermal delivery compositions and methods
UA48973C2 (uk) Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
NZ615430A (en) Method for on-demand contraception
GEP20053586B (en) Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same
WO2008049516A3 (de) Transdermales therapeutisches system enthaltend norelgestromin zur kontrazeption und hormonsubstitution
AR048722A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
NI201000184A (es) Composiciones y métodos para tratar el cáncer del seno.
CA2431645A1 (en) Methods of treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2007022061A3 (en) Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
LaGuardia et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception
WO2011126810A3 (en) Intravaginal drug delivery device
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
NZ627242A (en) Transdermal hormone delivery
MY136880A (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AR070302A1 (es) Composicion farmaceutica de un sistema de liberacion vaginal de esteroides
Sitruk-Ware Routes of delivery for progesterone and progestins
MXPA05003364A (es) Parche transdermico de 17(-estradiol/levonorgestrel para hormonoterapia restitutiva.
MX2010002190A (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometriosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
TW200605891A (en) Use of 7-t-butoxyiminomethylcamptothecin for the preparation of a medicament for the treatment of uterine neoplasms

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 DEC 2017 BY THOMSON REUTERS

Effective date: 20140912

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2018 BY CPA GLOBAL

Effective date: 20171102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2019 BY CPA GLOBAL

Effective date: 20181102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2020 BY CPA GLOBAL

Effective date: 20191031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2021 BY CPA GLOBAL

Effective date: 20201105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2022 BY CPA GLOBAL

Effective date: 20211104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2023 BY CPA GLOBAL

Effective date: 20221108

ASS Change of ownership

Owner name: THE POPULATION COUNCIL, INC., US

Effective date: 20230131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2024 BY CPA GLOBAL

Effective date: 20231102

LAPS Patent lapsed